GT Biopharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.245
- Today's High:
- $0.26
- Open Price:
- $0.2593
- 52W Low:
- $0.18
- 52W High:
- $2.3
- Prev. Close:
- $0.25
- Volume:
- 172031
Company Statistics
- Market Cap.:
- $10.16 million
- Book Value:
- 0.289
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -59.34%
- Return on Equity TTM:
- -107.96%
Company Profile
GT Biopharma Inc had its IPO on 2017-09-22 under the ticker symbol GTBP.
The company operates in the Healthcare sector and Biotechnology industry. GT Biopharma Inc has a staff strength of 2 employees.
Stock update
Shares of GT Biopharma Inc opened at $0.26 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.25 - $0.26, and closed at $0.26.
This is a +2.4% increase from the previous day's closing price.
A total volume of 172,031 shares were traded at the close of the day’s session.
In the last one week, shares of GT Biopharma Inc have slipped by -8.9%.
GT Biopharma Inc's Key Ratios
GT Biopharma Inc has a market cap of $10.16 million, indicating a price to book ratio of 2.8572 and a price to sales ratio of 0.
In the last 12-months GT Biopharma Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-6760000. The EBITDA ratio measures GT Biopharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, GT Biopharma Inc’s operating margin was 0% while its return on assets stood at -59.34% with a return of equity of -107.96%.
In Q2, GT Biopharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
GT Biopharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.42 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into GT Biopharma Inc’s profitability.
GT Biopharma Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.7506. Its price to sales ratio in the trailing 12-months stood at 0.
GT Biopharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $18.14 million
- Total Liabilities
- $4.84 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
GT Biopharma Inc ended 2024 with $18.14 million in total assets and $0 in total liabilities. Its intangible assets were valued at $18.14 million while shareholder equity stood at $11.76 million.
GT Biopharma Inc ended 2024 with $0 in deferred long-term liabilities, $4.84 million in other current liabilities, 41000.00 in common stock, $-676687000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $2.77 million and cash and short-term investments were $17.97 million. The company’s total short-term debt was $120,000 while long-term debt stood at $0.
GT Biopharma Inc’s total current assets stands at $18.02 million while long-term investments were $0 and short-term investments were $15.21 million. Its net receivables were $0 compared to accounts payable of $3.50 million and inventory worth $0.
In 2024, GT Biopharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, GT Biopharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.26
- 52-Week High
- $2.3
- 52-Week Low
- $0.18
- Analyst Target Price
- $3.5
GT Biopharma Inc stock is currently trading at $0.26 per share. It touched a 52-week high of $2.3 and a 52-week low of $2.3. Analysts tracking the stock have a 12-month average target price of $3.5.
Its 50-day moving average was $0.28 and 200-day moving average was $0.59 The short ratio stood at 0.83 indicating a short percent outstanding of 0%.
Around 540.8% of the company’s stock are held by insiders while 1327.4% are held by institutions.
Frequently Asked Questions About GT Biopharma Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.